Immunoglobulin SC, Cuvitru®

Cuvitru® dosing may be weight based; ensure accuracy of documented weight before administration	
Caution High Risk rating	
Form & Storage	Vials containing Normal Human Immunoglobulin (SCIg) **200 mg/mL** solution for subcutaneous injection 1g in 5mL, 2g in 10mL, 4g in 20mL, 8g in 40mL or 10g in 50mL of solution in a vial Store at **room temperature**. In case the product is stored in a refrigerator, the unopened vials must be placed at room temperature for a minimum of 90 minutes prior to use and kept at room temperature during administration.
Reconstitution	Already in solution. **Do not dilute**
Compatibility & Stability	Cuvitru® should be inspected visually for particulate matter and discoloration prior to administration. Do not use if particulate matter and/or discoloration is observed. The infusion must be started immediately upon transfer of Cuvitru® into the syringe
Administration	**Subcutaneous Infusion**
	The dose and dose regimen is dependent on the indication and Consultant instruction • The dose regimen should achieve a trough level of IgG (measured before the next infusion) of at least 5 to 6 g/L and aim to be within the reference interval of serum IgG for age. • A loading dose of at least 0.2 to 0.5g/kg (1 to 2.5mL/kg) body weight may be required. This may need to be divided over several days, with a maximum daily dose of 0.1 to 0.15 g/kg. After steady state IgG levels have been attained, maintenance doses are administered at repeated intervals to reach a cumulative monthly dose of the order of 0.3 to 1.0 g/kg. • Sub cutaneous via specific infusion pump, multiple sites can be used • Infusions are carried out in the infusion unit to assess patient suitability for home therapy. It is recommended to use an initial administration speed of 10 mL/h/infusion site. If well tolerated, the rate of administration may be increased at intervals of at least 10 minutes to a maximum of 20 mL/h/infusion site for the initial two infusions.

Documentation Requirements	This is a blood product, therefore batch and expiry should be recorded in patient's notes.
Monitoring	Vital signs pre and post infusion. SC injection site/s. Plasma IgG levels Patients naive to human normal immunoglobulin, patients switched from an alternative immunoglobulin product or when there has been a long interval since the previous infusion should be monitored during the first infusion and for the first hour after the first infusion All other patients should be observed for at least 20 minutes after administration
Adverse Drug Reactions	Infusion related reactions, localised or systemic Avoid potential complications by injecting the product slowly
Additional Information	The administration is foreseen to take up to two hours. Should an administration shorter than two hours not be possible due to required dose or administration rate of Cuvitru®, the required dose is to be portioned and administered at different infusion sites. If Cuvitru® remains in siliconized syringes for more than two hours, visible particles may form. Assess level of understanding and compliance with treatment Ensure that the patient and family member are educated and proficient in carrying on this treatment at home Usually, three SC infusions in the Infusion Unit.

Information provided relates to Cuvitru® (Takeda)